Biomunex Announces Exclusive Worldwide License Agreement with Ipsen

Deal News | Dec 04, 2024 | Goodwin

Biomunex Pharmaceuticals, a Paris and Cambridge-based biopharmaceutical entity, has entered an exclusive worldwide licensing agreement with Ipsen, a prominent biopharmaceutical leader. Under this arrangement, Ipsen has acquired the rights to develop, manufacture, and commercialize BMX-502, a novel T cell engager currently in preclinical development. This groundbreaking agreement enhances Ipsen's pipeline in immuno-oncology and strengthens its focus on therapeutic areas such as Oncology, Rare Diseases, and Neuroscience. As a MAIT cell activator, BMX-502 presents a pioneering approach in targeting a specific subset of T cells to destroy cancer cells effectively. Goodwin Paris advised Biomunex in this landmark transaction with a diverse team led by Marie Fillon, encompassing regulatory and compliance aspects. This partnership aims to expedite the development of BMX-502, unlocking potential first-in-class treatment options for cancer patients globally.

Sectors

  • Biopharmaceuticals
  • Immuno-Oncology
  • Legal Advisory

Geography

  • France – Biomunex Pharmaceuticals is based in Paris, France, emphasizing the importance of this geography in the transaction.
  • USA – Biomunex also operates in Cambridge, MA, and has interactions with Ipsen's wider global presence, indicating the cross-border nature of the agreement.

Industry

  • Biopharmaceuticals – The article involves companies focused on biopharmaceutical innovations, specifically within the development of cancer treatments.
  • Immuno-Oncology – The release of BMX-502 as a therapeutic in immuno-oncology highlights advancements in targeting cancer through novel T cell engagers.
  • Legal Advisory – The participation of Goodwin Paris in advising Biomunex underscores the relevance of legal advisory to ensure compliance and regulatory alignment in licensing agreements.

Financials

    Participants

    NameRoleTypeDescription
    Biomunex PharmaceuticalsTarget CompanyCompanyA biopharmaceutical company involved in the agreement to license its BMX-502 program to Ipsen.
    IpsenBidding CompanyCompanyA global biopharmaceutical leader that obtained exclusive rights to develop and commercialize BMX-502.
    GoodwinLegal AdvisorCompanyAdvised Biomunex Pharmaceuticals on the licensing agreement.
    Marie FillonLead AdvisorPersonLed the Goodwin team advising Biomunex on the legal aspects of the transaction.